Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Thoracic 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 12Stomach Neoplasms 10Neoplasm Metastasis 10Esophageal Squamous Cell Carcinoma 9Advanced Solid Tumor 9Carcinoma, Hepatocellular 7Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumor 4Melanoma 4Lung Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Neoplasms 3Lymphoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumors 2Sarcoma 2Neuroendocrine Tumors 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Colonic Neoplasms 2

Interventions

Rituximab 63Cyclophosphamide 37Brentuximab Vedotin 22Bendamustine Hydrochloride 22pembrolizumab 20fludarabine 20Gemcitabine 20Doxorubicin 20Prednisone 19ibrutinib 17Vincristine 16obinutuzumab 14Lenalidomide 13Nivolumab 10Rifampin 8parsaclisib 7duvelisib 7atezolizumab 7Vorinostat 7Dexamethasone 7Azacitidine 7spartalizumab 6loncastuximab tesirine 6MLN 8237 6venetoclax 5ixazomib 5glofitamab 5fludarabine phosphate 5durvalumab 5acalabrutinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma × tislelizumab × Clear all
NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

BeiGene

Phase 1/2 Completed
53 enrolled 17 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT04261439 2025-05-06

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Novartis

Phase 1 Terminated
60 enrolled
DermatologicLymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeiGene

Phase 1 Completed
75 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡